抗生素耐受现象日益严重,迫切需要研发新型抗菌药物。Plectasin是第一例报道的真菌防御素,其抗菌谱窄,仅对革兰氏阳性菌具有强大的杀菌活性,对其进行结构改造可进一步提高其抗菌作用特异性。Plectasin抗菌机制明晰,作用于细胞壁合成。其药物代谢动力学研究较为透彻,同时可在体外高产量表达且活性更高。这些研究为其应用提供了理论基础。综上,plectasin具有极大的临床应用潜力。
With the growing antibiotic resistance, there are urgent demands to develop novel antimicrobial agents. Plectasin is the first reported fungal defensin with strong and specific bactericidal activity against gram-positive bacteria. Structural reconstruction to plectasin can enhance its specificity to bacteria. It can inhibit synthesis of cell wall, to further kill bacteria. Moreover, there are many studies about its pharmacokinetics and in vitro expression with high yields and high activity. All these results provide a theoretical basis for its clinical application. Accordingly, plectasin has great potential to be developed as an antimicrobial agent.